These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11729832)

  • 1. The immunological basis of current and novel therapies of multiple sclerosis.
    Dubois B; Opdenakker G
    Arch Immunol Ther Exp (Warsz); 1999; 47(1):7-16. PubMed ID: 11729832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current evidence and therapeutic strategies for multiple sclerosis.
    Wingerchuk DM
    Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opportunistic infections and other risks with newer multiple sclerosis therapies.
    Berger JR; Houff S
    Ann Neurol; 2009 Apr; 65(4):367-77. PubMed ID: 19399841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis: early management.
    Zajicek J
    Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):137-40. PubMed ID: 9166373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological basis for the therapy of multiple sclerosis.
    Hohlfeld R
    Acta Neurol Belg; 1999 Mar; 99(1):40-3. PubMed ID: 10218091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of multiple sclerosis].
    Miyatake T
    Rinsho Shinkeigaku; 1984 Dec; 24(12):1232-4. PubMed ID: 6085568
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments.
    Galimberti D; Bresolin N; Scarpini E
    Expert Rev Neurother; 2004 May; 4(3):439-53. PubMed ID: 15853541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving therapies for multiple sclerosis.
    Korniychuk E; Dempster JM; O'Connor E; Alexander JS; Kelley RE; Kenner M; Menon U; Misra V; Hoque R; Gonzalez-Toledo E; Schwendimann RN; Smith S; Minagar A
    Int Rev Neurobiol; 2007; 79():571-88. PubMed ID: 17531859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pragmatic approach to treatments in multiple sclerosis].
    Vermersch P
    Rev Neurol (Paris); 2009 Apr; 165 Spec No 2():F125-31. PubMed ID: 19593885
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple sclerosis: new treatment trials and emerging therapeutic targets.
    DeAngelis T; Lublin F
    Curr Opin Neurol; 2008 Jun; 21(3):261-71. PubMed ID: 18451708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple sclerosis].
    Confavreux C; Gignoux L
    Rev Prat; 2002 Mar; 52(5):529-38. PubMed ID: 11949507
    [No Abstract]   [Full Text] [Related]  

  • 16. [Interferon therapy in multiple sclerosis. Mechanism of action, side effects, results].
    Huber M
    Nervenarzt; 1988 Sep; 59(9):514-20. PubMed ID: 2460777
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug insight: using monoclonal antibodies to treat multiple sclerosis.
    Hohlfeld R; Wekerle H
    Nat Clin Pract Neurol; 2005 Nov; 1(1):34-44. PubMed ID: 16932490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The implications of immunogenicity for protein-based multiple sclerosis therapies.
    Cohen BA; Oger J; Gagnon A; Giovannoni G
    J Neurol Sci; 2008 Dec; 275(1-2):7-17. PubMed ID: 18822434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New directions in MS therapeutics: vehicles of hope.
    Fox RJ; Ransohoff RM
    Trends Immunol; 2004 Dec; 25(12):632-6. PubMed ID: 15530830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.